66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 42-43

Impact of the 7-Gene Predictive Biosignature on Adjuvant Radiation Recommended by Black or White Race

Impact of the 7-Gene Predictive Biosignature on Adjuvant Radiation Recommended by Black or White Race

Background

Previous studies have demonstrated that compared with White women, Black women are more likely to have second tumors (invasive and noninvasive) in either breast or die of invasive breast cancer (IBC) after ductal carcinoma in situ (DCIS). Although multiple studies have presented results on the treatment of IBC, there are very few studies examining the impact of race/ethnicity on the treatment of DCIS. Thus, there is a need to further determine whether biologic or clinicopathologic factors are associated with the recommendation of therapy for DCIS in patients from different races/ethnicities. In this study, we evaluated the decision impact for radiotherapy (RT) recommendations incorporating the 7-gene predictive biosignature by race (White vs Black) in women with DCIS enrolled in the PREDICT study.

Methods

The PREDICT study was a prospective, multi-institutional registry for patients who received DCISionRT testing as part of their routine care. The registry included females, age 26 and older, who were diagnosed with DCIS and were candidates for BCS and eligible for adjuvant RT or systemic therapy. Treating physicians completed treatment recommendation forms before and after receiving test reports to capture surgical, radiation, and endocrine therapy treatment recommendations and patient preferences. The primary end point was to identify the proportion of patients in whom testing led to a change in RT recommendation. Additional analyses included changes in recommendations in patient subgroups based on race/ethnicity. Changes in RT recommendation were analyzed by McNemar test.

Results

Analysis was performed in 2305 patients treated at 63 clinical sites. Overall, 81% of the patients were White and 11% of patients were Black. No significant differences were observed in the distribution of Black and White in clinicopathological factors where the median age was 63 in White patients and 62 in Black pateints, with 34% of Whites and 28% of Blacks having nuclear grade 3. Overall, RT recommendations were changed significantly in 39% and 37% of White (P <.0001) and Black patients (P = .0032), respectively. Pretest the rates of RT recommendation were not different between the Black and White patients (P = .8). Posttesting, there was a significant difference in the net change of RT recommendation in Black (P = .01) and White (P <.001) patients, where Black patients had a 10% higher rate of RT recommendation when compared with White patients (P = .004). Furthermore, 33% of the Black women and 41% of White women who were recommended to receive RT pretesting were not recommended to receive RT post-testing (P = .10). In addition, 46% of Black women who were initially not recommended to receive RT pretesting were recommended to receive RT posttesting in contrast to 33% of White women (P = .04). In contrast, there were no significant differences observed in proportion in the DS groups 0-2, 2-4, and > 4 by Black vs White (P = .7).

Conclusions

This analysis demonstrates significant changes in recommendations to add or omit RT based on the 7-gene predictive biosignature in 2305 patients. Black patients had significantly higher rates of RT recommendation compared with White women with similar biosignature scores, suggesting that clinicians may be influenced by prior reports of greater risk in the Black population.

Articles in this issue

47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
48 The Era ‘or Error’ of Second Localization Procedures
48 The Era ‘or Error’ of Second Localization Procedures
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast  Cancer in the United States by Palliative Care Utilization
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content